A prospective descriptive 1‐year study in France of all BCG therapy dispensations for non‐muscle‐invasive bladder cancer. (14th December 2022)

• Record Type: Journal Article
• Authors: Neuzillet, Yann; Leon, Priscilla; Seisen, Thomas; Allory, Yves; Audenet, François; Loriot, Yohann; Masson‐Lecomte, Alexandra; Mejean, Arnaud; Pradère, Benjamin; Roumiguié, Mathieu; Traxer, Olivier; Xylinas, Evanguelos; Fournier, Georges; Roupret, Morgan
• Is Part Of: BJU international. Volume 131:Number 5(2023)
• Page Start: 611
• Page End: 616
• Publication Date: 2022-12-14
• Subjects: adjuvant treatment -- carcinoma in situ -- induction therapy -- intravesical BCG -- maintenance therapy -- non‐muscle‐invasive bladder cancer -- prescriptions -- recurrence -- risk -- bladder cancer; Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.15941
• Languages: English
• ISSNs: 1464-4096

Abstract

Abstract : Objectives: To describe the clinico‐pathological characteristics of non‐muscle‐invasive bladder cancer (NMIBC) treated in metropolitan France over 1 year when bacille Calmette‐Guérin (BCG) was subject to a national quota, and to document, in the context of recurrent shortages of intravesical BCG for NMIBC, the real‐life indications for adjuvant treatment. Materials and Methods: Between February 2021 and February 2022, the French National Agency for the Safety of Medicines (ANSM) asked the French Association of Urology to propose a science‐based quota solution for BCG using a clinical score. The ANSM then asked the distributor of the drug, MEDAC, to collect the scores for all patients for whom BCG was requested by healthcare institutions and to prioritize the requests for patients with the highest scores. Tumour stage, grade, size, number, time to recurrence, carcinoma in situ, age, accessibility of alternative treatments (total cystectomy, radio‐chemotherapy, thermo‐chemotherapy) and BCG treatment progress (initiation or maintenance) were documented for each intravesical BCG prescription. A descriptive analysis of the data collected during the quota year was performed. Results: During the 1‐year quota, 25 878 requests for BCG were made for 19 024 patients, 60.5% of whom were aged ≥70 years. Requests for induction and maintenance treatment accounted for 12 704 (49.1%) and 13 174 prescriptions (50.9%), respectively. NMIBC treated with BCG maintenance therapy was more frequently high‐risk NMIBC (91.7% vs 90.2%; P < 0.0001) than NMIBC for which induction therapy was requested. The number of cases of NMIBC leading to BCG adjuvant treatment was estimated at 12 704 cases/66 062 188 inhabitants over 1 year in metropolitan France. Conclusions: Our data suggest that the incidence of NMIBC at high risk of recurrence and progression is underestimated in reference epidemiological studies. These results should help to better define future care needs.